These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
541 related articles for article (PubMed ID: 27478924)
1. Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance. Aagaard L; Hallgreen CE; Hansen EH Int J Obes (Lond); 2016 Nov; 40(11):1742-1747. PubMed ID: 27478924 [TBL] [Abstract][Full Text] [Related]
2. Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006. Aagaard L; Nielsen LH; Hansen EH Drug Saf; 2009; 32(11):1067-74. PubMed ID: 19810778 [TBL] [Abstract][Full Text] [Related]
3. Adverse drug reactions in the paediatric population in Denmark: a retrospective analysis of reports made to the Danish Medicines Agency from 1998 to 2007. Aagaard L; Weber CB; Hansen EH Drug Saf; 2010 Apr; 33(4):327-39. PubMed ID: 20297864 [TBL] [Abstract][Full Text] [Related]
4. The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database. Gorelik E; Gorelik B; Masarwa R; Perlman A; Hirsh-Raccah B; Matok I Int J Obes (Lond); 2020 May; 44(5):1021-1027. PubMed ID: 32152496 [TBL] [Abstract][Full Text] [Related]
5. Adverse drug reactions reported by consumers for nervous system medications in Europe 2007 to 2011. Aagaard L; Hansen EH BMC Pharmacol Toxicol; 2013 Jun; 14():30. PubMed ID: 23763896 [TBL] [Abstract][Full Text] [Related]
6. Spontaneous reports of vaccination errors in the European regulatory database EudraVigilance: A descriptive study. Hoeve CE; van Haren A; Sturkenboom MCJM; Straus SMJM Vaccine; 2018 Dec; 36(52):7956-7964. PubMed ID: 30416019 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys. Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758 [TBL] [Abstract][Full Text] [Related]
8. Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013-2020. Alsuhibani A; Alrasheed M; Gari M; Hincapie AL; Guo JJ Int J Clin Pharm; 2022 Feb; 44(1):172-179. PubMed ID: 34564826 [TBL] [Abstract][Full Text] [Related]
9. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems. Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026 [TBL] [Abstract][Full Text] [Related]
10. Patient Reporting in the EU: Analysis of EudraVigilance Data. Banovac M; Candore G; Slattery J; Houÿez F; Haerry D; Genov G; Arlett P Drug Saf; 2017 Jul; 40(7):629-645. PubMed ID: 28417320 [TBL] [Abstract][Full Text] [Related]
11. Paediatric adverse drug reactions following use of asthma medications in Europe from 2007 to 2011. Aagaard L; Hansen EH Int J Clin Pharm; 2014 Dec; 36(6):1222-9. PubMed ID: 25288145 [TBL] [Abstract][Full Text] [Related]
12. Adverse drug reactions in children reported by European consumers from 2007 to 2011. Aagaard L; Hansen EH Int J Clin Pharm; 2014 Apr; 36(2):295-302. PubMed ID: 24190692 [TBL] [Abstract][Full Text] [Related]
13. Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016. Ran J; Yang JY; Lee JH; Kim HJ; Choi JY; Shin JY Int J Clin Pharm; 2019 Oct; 41(5):1365-1372. PubMed ID: 31313003 [TBL] [Abstract][Full Text] [Related]
14. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports. Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292 [TBL] [Abstract][Full Text] [Related]
15. Estimating Adverse Events Associated With Herbal Medicines Using Pharmacovigilance Databases: Systematic Review and Meta-Analysis. Kongkaew C; Phan DTA; Janusorn P; Mongkhon P JMIR Public Health Surveill; 2024 Aug; 10():e63808. PubMed ID: 39208414 [TBL] [Abstract][Full Text] [Related]
16. An analysis of the trends, characteristics, scope, and performance of the Zimbabwean pharmacovigilance reporting scheme. Masuka JT; Khoza S Pharmacol Res Perspect; 2020 Oct; 8(5):e00657. PubMed ID: 32930524 [TBL] [Abstract][Full Text] [Related]
17. Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance. Pinheiro L; Blake K; Januskiene J; Yue QY; Arlett P Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):705-12. PubMed ID: 27004571 [TBL] [Abstract][Full Text] [Related]
18. Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance. Blake KV; Zaccaria C; Domergue F; La Mache E; Saint-Raymond A; Hidalgo-Simon A Paediatr Drugs; 2014 Aug; 16(4):309-19. PubMed ID: 24898717 [TBL] [Abstract][Full Text] [Related]
19. Signal Detection for Cardiovascular Adverse Events of DPP-4 Inhibitors Using the Korea Adverse Event Reporting System Database, 2008-2016. Yi H; Lee JH; Shin JY Yonsei Med J; 2019 Feb; 60(2):200-207. PubMed ID: 30666842 [TBL] [Abstract][Full Text] [Related]
20. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database. Roberto G; Piccinni C; D'Alessandro R; Poluzzi E Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]